Neuracle NEO Cleared as World's First Invasive BCI
Key insights
- NEO's eight sensors sit on the dura mater rather than penetrating the cortex, making it less invasive than Neuralink's N1 and enabling expedited regulatory approval.
- Neuracle Technology conducted 36 clinical trials before approval, with 32 completed in 2025, compressing years of evidence into a single year.
- China added NEO to its national health insurance system immediately upon approval, assigning a unique reimbursement code for eventual partial patient coverage.
Why this matters
China has cleared both regulatory and reimbursement hurdles for invasive neurotechnology simultaneously, giving Neuracle Technology a commercial lead that competitors must measure in years. The dura mater sensor approach NEO uses is now a validated less invasive pathway that companies like Neuralink must account for when building their own regulatory strategies. China also folded NEO into national health insurance on launch day, establishing state coverage of invasive neurotechnology as a real policy precedent other governments will be forced to respond to.
Summary
China's National Medical Products Administration approved NEO as the world's first invasive BCI for commercial use. Neuracle Technology and Tsinghua University placed eight sensors on the dura mater instead of the cortex, a design that earned expedited review over Neuralink's N1 chip.
Essentially: (Neuracle Technology, Tsinghua University) moved invasive BCI from clinical trials into a nationally reimbursed healthcare market.
- Dong Hui, paralyzed six years in a car accident, wrote his name after 11 months of daily robotic glove training.
- 36 clinical trials, 32 completed in 2025; NEO entered China's national health insurance at launch.
- Cleared for patients aged 18-60 with spinal cord injuries and residual arm function.
China's five-year plan lists BCI alongside quantum computing and humanoid robots as a strategic priority, with Beinao-1 potentially cleared by 2028.
Potential risks and opportunities
Risks
- Neuracle's 36-trial evidence base is thin for a commercial launch; a serious adverse event at scale could trigger regulatory recall and reset the global BCI approval timeline.
- Neuralink, whose N1 chip penetrates the cortex rather than resting on the dura mater, now faces a commercially approved competitor in the world's largest paralysis patient population before its own commercial launch.
- Partial insurance coverage with no disclosed reimbursement rate could leave most Chinese patients unable to afford NEO, producing adoption failure despite regulatory success.
Opportunities
- Soft robotics makers supplying rehabilitation exoskeleton components stand to benefit as NEO drives demand for robotic glove systems across Chinese hospitals and rehab centers.
- BCI startups using dura mater or epidural sensor architectures now have a regulatory precedent from China's National Medical Products Administration to cite when approaching the FDA or EMA.
- Beinao-1 and other Chinese BCI devices targeting 2028 approval create a procurement planning window for Chinese health systems building out neurotechnology rehabilitation infrastructure.
What we don't know yet
- Out-of-pocket costs are unspecified; the article notes a unique insurance code but gives no reimbursement rate or patient share.
- Whether Neuracle Technology has initiated regulatory filings with the FDA, EMA, or other international bodies is not addressed.
- Long-term safety data beyond 11 months for dura mater sensor placement has not been published or cited.
Originally reported by technologyreview.com
Read the original article →Original headline: China Approves World's First Invasive Brain-Computer Interface for Commercial Use Beyond Clinical Trials